Trecadrine
Anti-ulcer drug
From Wikipedia, the free encyclopedia
Trecadrine (INN) is a drug that was originally developed as an anti-ulcer agent but was found to act as a β3-adrenergic receptor agonist with potential anti-obesity and anti-diabetic properties.[2][3][1][4] It is selective for the β3-adrenergic receptor, lacking activity at the β1- and β2-adrenergic receptors.[1] The drug is orally active.[1] Structurally, trecadrine is a substituted β-hydroxyamphetamine and derivative of β-hydroxy-N-methylamphetamine (ephedrine, pseudoephedrine) with a tricyclic moiety attached at the amine.[2][5]
| Clinical data | |
|---|---|
| Routes of administration | Oral[1] |
| Drug class | Sympathomimetic; β3-Adrenergic receptor agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C27H29NO |
| Molar mass | 383.535 g·mol−1 |
| 3D model (JSmol) | |
| |
| |